## ## ## ## ## ## ||SECTION 172STATEMENT: STAKEHOLDER ENGAGEMENT|SECTION 172STATEMENT: STAKEHOLDER ENGAGEMENT|SECTION 172STATEMENT: STAKEHOLDER ENGAGEMENT|SECTION 172STATEMENT: STAKEHOLDER ENGAGEMENT|SECTION 172STATEMENT: STAKEHOLDER ENGAGEMENT|SECTION 172STATEMENT: STAKEHOLDER ENGAGEMENT|SECTION 172STATEMENT: STAKEHOLDER ENGAGEMENT| |---|---|---|---|---|---|---|---| ||TheTrustee|Directors consider that the decisions they have made during the financial|||||| ||year have satisfied||||the requirements
of5172(1)ofthe Companies Act 2006and they have||| ||acted ingood faith||||topromote the success ofthe Institute and, in doing so,have taken||| ||into account|the||stakeholders
and matters outlined
in5172(1).|||| ||TheTrustee|Board|||has the ultimate responsibility
forthe Institute and delivery ofits||| ||charitable objectives.||||||| ||Thetable below|||sets out Pirbright's
significant stakeholders.|||| |||||||"|| |OUR VALUES
Wetake PRIDE in
everything
wedowhich is
reflected in our values:|||'
,|drIpgk)S4ieij8ejNi.
. .
Ps" L
~r
v
"'j Weengagewithfundersatallstagesofthefundingprocessandhaveregular
„r.lr
.
~ dialogue'and
face to face meetings
with our key investors. Please seepage 20 21
(Jl formore information.|||| |||||||Weengage with the public through our Outreach and Public Engagement|| |mm-for the highest
qualitystandards,
delivery and||||||progra
mmes. These were severely affected in 2021,due tothe COVI0-I 9
pandemic, but events have resumed
in first quarter 2022.Please see page 18for|| |performance.~—in everything
wedo; leadership,
learning,
biossfety, problem anti cipation||||||more information.
Pirbright undertakes
numerous
collaborati
one with
universities,
research
institutes and disease control agencies around the world. More details are given
onpage 28.|| |and containmentofunexpected||||||Partnerships
with pharmaceutical
companies are essential forthe development|of| |events.~-isthe driving force||||||vaccines, diagnostics and medicines. Find out more onpage 25.|| |behind our fundamental
and||||||Weengage with the farming
community
through
specie listfarming press,|| |applied science. Our work is||||||through
farming organisations
and bodies and media outlets including 8 BC|| |positioned atthe cutting-edge||||||World Service and 8BCRadio 4Farming Today as well asatagricultural
events.|| |ofscience todeliver solutions|||||||| |forglobal good.
mmmmmI-we||||||Employee
En gage
ment
forms acentral part of the institute's strategy Weemploy
avariety ofways tocommunicate
with our staff
and students
in adialogue sowe|| |respect and tmst in our diverse||||||can also gain feedback. Communication
channels include amonthly e-newsletter,|| |community.||||||intranet, forums, staffbriefings,
surveys, digital screens, internal seminars, blogs|| |~-we aim todeliver
the best in all aspects of our
work, including scientific
research, health, safety,
biosafety, stakeholder|Iet)@I))OEI"|||sn||and workshops. Further information
about our employees canbefound from
page30.
One ofthe ways weengage with our suppliers
isthrough an Annual Supplier Day
held atPirbnght. However due tothe pandemicthis
wasnot possible but digital
*Nhhdr|| |supportand
protecting the
environment.|ljI ills||||,|Lh
Vht
lh
d
*h
2
the local community
inanumber ofways including sponsoring
local events,|| |Wetake PRIDEinbeingaworld-
class centre ofexcellence in||,I|L|||volunteering
in local conservation
initiatives including FoxCorner Conservation
and engaging
wrih the Parish, Borough and County Councils over development|| |scientific research, attracting
experts intheir field from around|RP|||||on our campus. Our scientists also visit local schools and colleges- more
information
canbefound onpage 18.|| |the world. This combined
with our drive forprofessional
excellence andriigorous||||||AsaMajor Hazard site, Plrbright works closely with the Health &Safety Executive
(H5E),counter terrorism security authorities,
Home Office and other regulators.
Ass National Capabilityfortheprevention
and controlofexoticviral
diseases|| |academic, biosafetyand
ethical||||||oflivestock, Pirbrightworkscloselywith
Defra, BBSRCUKRI and others. Asthe|| |standards allowsthe
Institute
tohave ameasurable
impact
on health and wellbeing and
economic and food security||||||World Reference Laboratory forcertain pathogens
and aregional Reference
Laboratoryfor others, Pirbrightworks
doselywith the UN Food 8IAgriculture
Organisation
(FAO)and World Organisation
forAnimal Health (WOAH). As
an ISO/IEC 17025accredited testing laboratory, Pirbright works with the UK|| |globally.||||||Accreditation
Service (UKAS).Seepage 15formore details.|| |||||||Pirbi'ight has avibrant student community,
and we are committed tosupporting,|| |||||||nurturing
and offering additional
learning and training
opportunities
to them.
Find out more onpage 33.|| ## ## ## ## |RISK'|||CQNNOL lBET(SATO))2|| |---|---|---|---|---| |EIOBAI'%(Y.|||PIDuicd, anginsudog,
opurut(mrd
and mwagement
measures for|| |, )E)f(@.gi, .(),
EX,
fl)T,
pig)If|||bioluglssl cents(hmsn)
In'camp(Erase wigr relevant UK'lsgIhji((on
(
'
i
a Path
EOgrdsr200S, Cimtmlofguf)
Hamrdotu to4((h~'20022 Qsrts(fcsgy Mo((Ad
organ'umi
(ctohu((nsjd vsp),Rsgulklcyns2014)md
ysexiiM
Appfovsd Cudes'o) PructfseuuA4'guhhv'Me;
lb El(BI(reer'Ifwhh (SO|| ||||900('I ISO) tIROI', )BOOS
Iand ISO43001IAlso, soa npal HSE.|| ||||Mfjor Hstard Interventiohr Plin, 'and Staffcolmrt ofcompetent Sarlsk|| ||||pfsptu'g, apefa(lo)dl aid mafragenventmstuurdr
for s'ecutity'in|| ||||confor(BEYwjth Ifcfriretrsnis ofthe UKNauoiial coI(nter Terrorism|| |Hotuo3NSEQUENeEP
PATH86EN)|||feC'ui'iiy Oghe
.W')j(cove)Ega hy rsglptrul
Co'uiiter'TSI)urbrh
SIyturity
ACh'riaeiur i2af/P'guard
fofcw, bu'drgreund
Straenlng
OfnaW
stavtu(Tk srfd'inukfp elayers ofp)srshil secs)hy.|| |QUAL(TY|||Accredltst(op R(the Reference latrarstories to $0/IEC 17025 by
the UKACchh)Wion'Bsrvge
(Pirbrlglit h UKASAccmditsd
Testkrg|| ||||'Liguustorygo'402S),
deva(op(turns
sn(fI(np(mnsntagen
ofa|| ||||E(uality msfmgtrnhgf
systim ac(usa)he
Instltu(s) sn Intefiial a2ufu
pre'granipw,
End alignment toISO9001andot¹r mlevant
ISO|| ||||tmrn'Sgemegt
sth)fdirdg(0
k'sy'openu(onaf
a(usa fur biitter support of|| ||||the Reisrenc'e Laboratories.|| |ANIMALWELPARE|||Physkml,
opsratiurwl
and managwnent
meauaes for an(mal walfam|in| ||||compgance with rehvant
UK legislitlbn
(Animal Sdem)fib Piocedures|| ||||Act 19B))and assoc(Ried Approved Codes ofPfactice'aru(guidance,|| ||||oversr(ghf liy OKNoire 6ffice, a'ppjication of Slys (Rsphice, Refine,|| ||||Reduce}and ARRIVE gu(dance (Animal Resesrds Rephrt(ng
In Vrvo|| |CYBERSEC0R(IY|||Expw'iments).
Comprehensive
portfolio of'tirchnical
countermeasures
sgd
msnagerrient
sy'st'sms for~Ih'corilonhitywjth|| ||||rscpgvprwms
ofthe UKNational Cyber SGCSTSy Omtr'a and HSE
Cugg'6~TIly isehdlremsnis
CrESIIRychgcd c'ontiol systims,
GEIth ahd s'egrugstum
ofafdcui Iesuurcm from networksitralnlng,
dr'Sls4euerclsss, snd allgmniiit
witirC)rbsr E)s'enhh Ptui.|| |CONTINUI(Y|||(nadet» snd crlslf nwrsrgegrsnt
piarw
Ibusiness corrt(nuhy
planning|| ||||in hsgdment
wkly lscyr 22201,hackr)ps(ind
contlg)(s)Kies foruitical|| ||||servic'essed
supplies, and contingency
PIsnsfor ths R+tenor
La
stories'foi disease autbr'asks,
with all pfans Iugdlariy'tested
by|| ||||ddjh 8exerdsis.|| ||||Recruitmint
0 retention
and rasportslbifrty's~,
traininif'
31
development
progmmrpas,
careerp~ with Itubsnd ment
awards and a'psfsohs( promogon
schein'e, isuipsl!Purformshce
arid|| ||||persensl deva(opmwn
reviews s) issoow peru(on piovh(on and life|| ||||Eoverr and emp(syau
herrefhs
pls(fhv(n and Mdistsrrceprog)pnme,|| ||||Rigorous stutervu forRr(andal planning,
contf9( and rmuiitoring,|| ||||o)rguihg fish muuagftnhrtt,
,proces)ss usl fpppoit to.fed(i(ate|| ||||pieparatlon,
subfnhiie0 std m'anagemtmt
ofcompegtivhbstding|| ||||grants snd csp(tff fgndlfI+gblds,
co(nitwrdafbtu)siss
de'vdlopldaiia|| ||||proygsmms
Plihdght'
Inrmvaiions
Ltdssa pdyssg vs)gda for|| ||||celhrnsrcfi( tvofk ctunpreherqiva
purtfd(id of kuu'rinse
fm((dss, snii-
fr'aud andEEId~ fujlfdas', anrwallsudl't',
,snd reportage toI(BSRC|| ||||furtdw';. fyri~'~Bud sfrataglo partnai|| ||||Pat(uniufactumdinobuf(tuwdpfsrmfnfy
hslhdbg|| ||||I jlcruufgi(n
Iucurhe'from
Eorhpetitiire' Rfisf(ng score)is snd|| ||||approprlatecomhwrc(ej
actlvjdes, md:
vins
from Img
vad|| ||||fuocuremwn
snd Bgskc fun(fed 'spend toEEwe' csfftafwo21GL|| • p rth*rrpNwJq ## ## klAZARD >44 G c 11 ¢• PP Viral SuFvivalcod@bre3king £a5EatTheFe5tivaloF Tomorrow. Swindon. ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## |||Note|Unrestricted|Itestrlcted|2022|2021| |---|---|---|---|---|---|---| ||||Funds|Funds|Totalfunds|Total Funds| ||||5'000|5'000|8'000|8'000| |Income from||||||| |Core strategic grant||||15,513|15.513|18/928| |Charitable activities||||||| |Grants and contracts|||16,281|24,904|41,185|58,190| |Other charitable
income|||1,453||1,452|2,609| |Investment
income|||959||959|956| |Total Income|||18,693|40,417|59,110|80,683| |Expenditure
on||||||| |Raising funds||||||| |Rental propenies
and tenant services|||309|315|624|636| |Investment
management|costs||19||19|18| |Charitable
activities||||||| |5cientific research|||32,701|11,187|43,888|44,850| |Rental properties
and tenant services|||||1,586|2,025| |Other chaditable activities|||||400|471| |Total expenditure|||34,413|12,105|46,518|48,000| |Net (gains) on Investments||||2.000|2,000|| |Net (expendaure)/income|before transfers||(15,720)|30,312|14.592|32,683| |Transfers between funds||15|15,513|(15,513)||| |Net movement
in funds|||(207)|14,799|14,592|32,683| |Balances brought
forward|||9,997|320,649|330,646|297,683| |Balances carried forward||16|9,790|335,448|345,238|330,646| |||||2022||2021| |---|---|---|---|---|---|---| ||||Note|8'000|5'000|5'000| |Fixed assets||||||| |Tangible fixed assets|||9|318,228|295,172|| |Investment
property|||10|2,000||| |||||320,228||295,172| |Current assets||||||| |Stocks|||11|359|264|| |Debtors|||12|10,703|13,397|| |Term deposits over|three months|||5,016|23,194|| |Cash at bank and in|hand|||29,495|19,237|| |||||45,573|56,092|| |Credkorsr amounts|falling due vrhhln one year||13|(20,5631|120.618)|| |Net current assets||||25,010||35,474| |Total assets less cermet liabili8es||||345,238||330,646| |Net assets||||345,238||330,646| |Financed by||||||| |Unrestricted
funds|||16|9.790||| |Restricted funds||||||| |Fixed asset fund|||15|330,243||317,191| |Investment
revaluation||reserve||2,000||| |Other resuicted reserves||||3,205||3,458| |Total funds||||345,238||330,646| |Approved
by the Board ofTrustee Directors||||Professor Vince Emery||| |on 16November 2022and signed on their||||Trustee Director||| |behalfon16November||2022.||||| |||||Rona Chester||| |The accompanying|notes on pages 48to|||Trustee Director||| |61forman integralpartofthesefinanoal||||||| |||||||||000|2022|f'000|2021| |---|---|---|---|---|---|---|---|---|---|---|---| ||||||||||f'000||f'000| |Ner cash provided byoperating activities|||||||||||| |Net movement
in funds||||||||14,592||32,683|| |Interest and rent receivable||||||||(959)||(956)|| |Depreciation
charged||||||||9,684||9,469|| |Increase in valuation ofInvestment|||Property|||||(2,000)|||| |(Increase)/decrease
in stocks||||||||(95)||42|| |Decrease/(increase)
in debtors||||||||2,694||(6,693)|| |Increase in creditors||||||||1,255||1,288|| |Net cash provided
by operating ectlvides|||||||||25,171||35,833| |Cash flows from investing activities:|||||||||||| |Interest and rents received||||||||959||956|| |Decrease/(Increase)
in cash|deposits|||&|3months|||18,178||(2,025)|| |Purchase of propeny,
plant|and equipment|||||||(34.050)||(35,056)|| |Net cash used in investment||activldes|||||||(14,913)||(36,125)| |Change in cash and cash equivalents|||||in the reporting|period|||10,258||(292)| |Cash and cash equivalents|at|the beginning ofthe reporting|||||||19,237||19,529| |period|||||||||||| |Cash and cash equivalents|at|the end|||ofthe reporting|period|||29,495||19,237| |Cash and cash equivalents|asabove||||||||29,495||19,237| |||||||||finnan|||| |Cash placed on term deposits||longer||than 3months|||||5,016||23.194| |Cash at bank and In hand|||||||||34,511||42,431| ||||||||||Asat||Asat| |Net cash at Bank||||||||1|Apdl 2021
5'000|Cashgow
f'000|31 March 2022
5'000| |Cash at Bank|||||||||19,237|10,258|29,495| |Total|||||||||19,237|10,258|29,495| |The accompanying
notes on pages|||48to6) form an integral||||part of these|as Istatements|||| ## ## ## ## ## ## ## ## ## ## ## |||2022|2021| |---|---|---|---| |||f'000|2'000| |BBSRCUKRI —core strategic grant||15,513|'I5,449| |Resource concdibution|grants||3,479| |||15,513|18,928| ## |INCOME FROM CHARITABLE ACTIVITIES||| |---|---|---| ||2022|2021| ||f'000|f'000| |Grant inmme||| |BBSRCUKRI —research grants|3,522|| |BBSRCUKRI-other grants|25,375|43,885| |Other research grants|12,288|'I1,345| ||41,185|58,190| |Other charitable activities|1,453|2,609| ||42,638|| ||2022|2021| |---|---|---| ||f'000|f'000| |United Kingdom|37,909|55,636| |Europe|569|1,106| |North America|2,944|2,573| ||1,216|1,484| ||42,638|60,799| ## |INCOME FROM||CHARIT|A|BLE ACTIVITIES|(CONTI||| |---|---|---|---|---|---|---|---| |||||||Restricted|2022| |||||||f'000|Total| ||||||||f'000| |Cunent year|||||||| |Analysis ofgrant income|||||||| |BBSRCUKRI|||||||| |Competitive
Project||Grant —research grants|||3,522||3,522| |Other grants|||||471|24,904|25,375| |Total BBSRCUKRI||||||24,904|28,897| |Defra "Umbrella" commission|||projects||2,395||2,395| |Defra Surveillance|||||3,043||3,043| |Other government|departments,|||public sector|665||665| |European
Union|||||569||| |Industry.
levy boards|||||1,572||1,572| |Trusts, foundations,||charities|||906||| |Other research grant income|||||3.138||3,138| |Total Income-grants indudlng||||research|16,281|24,904|41,185| ||||||||2021| ||||||Unrestricted||Total| ||||||f'000||f'000| |Prior year|||||||| |Analysis ofgrant income|||||||| |BBSRCUKRI|||||||| |Competitive
project||Grant —research grants|||2,960||2,960| |Other grants|||||198|43,687|| |Total BBSRCUKRI|||||3.15$||| |Defra "Umbrella" Commission projects|||||2,250||2,250| |Defra Surveillance|||||2,697||2,697| |Other government|departments,|||public sector|||540| |European
Union|||||1,106||1,106| |Industry,
levy boards|||||1,176||1,176| |Trusts, foundations,|charities||||1,003||1,003| |Other research grant||income|||2,573||2,573| |Total Income- grants indudlng||||resewch|14,503|43,687|5$,190| ## ## |Other charitable income consists ofna|des and activities which are ancillary
to the chadita|ble activities ofthe institute:|| |---|---|---|---| ||Unresaicted|2022|2021| ||f'000|Total|Total| |||f'000|2'000| |Royalties||373|388| |Diagnostic testing|317|317|183| |Supply ofreagents|247|247|277| |Other|516|516|1,761| ||1,453||2,&09| ## ||||||2022|2021| |---|---|---|---|---|---|---| ||||||5'000|f'000| |Rental|income|and|tenant|services|930|849| |Bank|interest|||||107| ||||||959|956| ## |4ANALYSIS OF EXP|ENDITURE||||| |---|---|---|---|---|---| ||||Other direct|AEocebul|2022| |Current year|||costs
LR000|support costa
f'000|Total
f'000| |Unrestricted
funds|||||| |Costs ofraising funds|||||| |Rental income and tenant|services||||| |Investment
management|costs||10||19| |Charitable
expenditure|||||| |Grants forscientific research||13,131|7,521|12,045|32,697| |Rental income and tenant|services|||988|988| |Other charitable activities||||212|| |Total unrestricted
expenditure||13.131|7,719|13,563|34,413| |Restricted funds|||||| |Cost ofraising funds||||316|316| |Charitable expenditure||||11,789|11,789| |Total restricted expenditure||||12,105|12,105| |Total expenditure||13.131|7,719|25,6fi8|46,518| |Total expenditure
-ZOZI||13,620|6,251|28,129|| |Included
in allocated support costs are staffcostsoff4978K(2021:f5034(q|||||| |||Staffcosts|Other|Allocated|2021| |Prior year||f'000|direct costs
f'000|support casts
f'000|Total
5'000| |Unrestricted
funds|||||| |Cosrs ofraising funds|||||| |Rental income and tenant|services|||312|312| |Investment
management|costs||||18| |Charitable
expenditure|||||| |Grants for scientTiic research||13,620|6,043|'I1,976|31,639| |Rental income and tenant|services||(7l|970|963| |Other charitable activities|||206|216|42Z| |Total unrestricted
expenditure||13,620|6,251|13,483|33,354| |Restricted funds|||||| |Cost ofraising funds|||||324| |Charitable
expenditure||||14,322|14,322| |Total unrestricted
expenditure||||14,646|14,646| |Total expenditure||13,620|6,251|28,129|48,000| ## |||Rental|Rental||owens md|Scnmc|||||||| |---|---|---|---|---|---|---|---|---|---|---|---|---|---| |||0|«etta|I«md«em|mnthach|rental hearten|||||||| |||snd tend«||wanasmwnt|formhntnc|wd «anne|||||||| |||||mmh|ms«sch|«evans|||||||| ||||2'000|f'000|orna|0000|||||||| |Cunant year|||||||||||||| |Unrestricted|||||||||||||| |Premises|||178||7,650|MB||67||8763|nds«as||ea| |Finanoal costs|||25|9|567|44||25|25|695|tlhe|snw|| |Management|||32||773|13||15|8|841|tnte|spent|| |Human resources|||54||398|||16|||||| |Information|technology||10||2,097|23||12|23|2165|||| |Procurement|||||473|18||12|6|515|Om|sp«»|| |Governance|||||87||||I|96|Om|spent|| ||||309|9|12,045|988||149|d3|13,563|||| |Depreciation|||||8,526|807||50||9,686|||| |Repairs / compliance|||13||2,278|128||||2,419|||| ||||316||10,804|935||50||12,105|||| |Total support costs|||625|9|22,849|1,923||199|d3|25.668|||| |||Immi||||Sd|||||||| |||h||Inwntm ant|conhads|nmht hm|||Oewr||||| |||andtmnmt||mmasemmn|Io sde
IN|andtwmnt||Stau|deelakl||||| ||||E'000|f'000|relmerdt
f'000|«selene
ESRN|I st|w ms st
ETEN|adishas
f'000|Tatal 202t
E'000|Sash al
aamaton||| |Prior year|||||||||||||| |Umestrlcted|||||||||||||| |Premises|||174||7,473|867||65||8579|No(Ewraraa||| |Financia Icosts|||27|9|593|46||27||728|tl~spent||| |Management|||39||953|17||19|10|1,038|||| |Human resources|||54||391|||16||461|time|spent|| |Information|technology||10||2,059|23|||23|2,126|||| |Purchasing|and|||||16|||5||tlm|spe t|| |procurement|||||||||||||| |Governance|||||83||||1|90|tittle|newt|| ||||312|9|11,97d|970||151|dg|13,483|||| |Depreoation|||||8,335|||||9.469|||| |Repairs / compliance|||28||4,876|273||||5,177|||| ||||324||13,211|1,062||49||14,646|||| |||||9|25,187|?032||200|65|28.129|||| ## ||||2021| |---|---|---|---| ||||5'000| |Net (expenditure)/Income|isstated after charging.||| |Auditor's
remuneration|||| |-audit seniices|||| |-noneudit
services (taxation advice)||21|12| |Depreciation||9,684|9,469| |Loss on foreign exchange translations||27|189| |Hire ofplant and machinery||22|17| |Rental oflend and buildings||55|52| ## ## ||||Number ofemployees|Number ofemployees| |---|---|---|---|---| ||||2022|2021| |Office, managementandestatesupport|||121|126| |Scientific||||247| ||||361|373| |he aggregate||payroll costs ofthese persons were as follows:||| ||||2022|2021| ||||E'000|E'000| |Wages and|salaries||13,967|14,103| |Social security||costs|1,432|1,418| |Other pension||costs|2,549|2,613| ||||17,948|18,134| ||||2022|2021| |Termination|payments:||8'000|E'000| |Redundancy|||148|168| |||||168| |The numbe|r ofstaff with em|oluments
grea|ter than E6| |---|---|---|---| |||2022|2021| |||Number|Number| |||13|13| |E70,000|—E79,999|6|| |E80,000|—E89,999|3|4| |B6,000|—E99,999|4|4| |5110,000|—E119,999
earning|1|1| |5140,000|—5149.999|1|1| ## ## |of100ordi|nary|shares ofEieach.|shares ofEieach.||| |---|---|---|---|---|---| |The assets|and|liabilities ofthe subsidiary were:|||| |||||2022|2021| |||||2'000|2'000| |Current assets|||||| |Creditors:|amounts||falling due viithin one year|(8)|(8)| |Net liabilities||||(8)|(8)| |Aggregate|share capital and reset ves|||(8)|(8)| ## |||2022|2021| |---|---|---|---| |||2'000|2'000| |At 1 April 2021|||| |Revaluation|in the year||| |At 31March|2022|2,000|| ## |11STOCKS|||||| |---|---|---|---|---|---| |||||2022|2021| |||||f'000|f'000| |Laboratory
consumables||||359|264| |The institute's stockconsists of||laboratory supp liesforresearch purposes.|||| |12DEBTORS:AMOUNTS||FALLING DUE WITHIN ONE YEAR|||| |||||2022|2021| |||||f'000|f'000| |Trade debtors||||1,848|2,181| |Prepayments||||1,663|1,539| |Accrued income||||6,996|2.321| |Other debtors||||196|7,356| |||||10,703|13,397| |13CREDITORS: AMOUNTS|||FALLING DUE WITHIN ONE YEAR||| |||||2022
f'000|2021
f'000| |Trade creditors||||3,547|2,484| |Taxation and social security||||156|550| |Other creditors|||||154| |Accruals||||5,276|7,655| |Deferred income||||11,094|9,285| |Short-term
compensated|absences||||490| |||||20,563|20,618| ## |||2022|2021| |---|---|---|---| |||f'000|f'000| |Accrued income||6,996|2,321| |Deferred income||(11,094)|(9,285)| |||(4098)|(6,944)| |Net deferred research grant income atthe beginning|ofthe year|(6,964)|(7,440)| |Research grant income received duding the year||(13,415)|(14,027)| |Research grant money released to SOFA during the|year|16,281|14,503| |||(4,098}|(6,964)| ## |15FUNDS|| |---|---| |Balance
Transfer
Balance|| |1Apr0
Net lncomel
between
31March|| |Current yean
2021
E'000
expendihne
f'000
funds
f'000
2022
E'000|| |Unrestricted
funds:|| |General
Designated
Restricted funds:
Fixed Asset Fund
Other restrinsed
funds:
Fixed Asset Project Support Costs
DP2 phase 2occupation
BBSRCUKRI core grant funding
Brooksby support mats
Inves**t**ment
property
revaluation
Other
7,504
2,493
317,191
593
1,224
1,573
(15,352j
(368)
13,394
(396)
(199)
15,513
15,263
(250)
(15,513)
7,415
2,375
330,243
539
1.025
1,573
2,000
68
330,646
14,592
345,238
Un**r**estrkted
designated
funds
Unrestricteddesignatedfundscompiisesums
setasideforspecificpurposesincludmg
the acquisition
andimprovementoftangiblefixed
assets,
the presentation
ofscientific conferences, and conuibutions
towards capital tobe replaced using the fully economic costing policy adopted
for
o her
p ojects|| |by the Institute
This includes E1,173kforoccupation costs relating tocapital projects (2021:E1,661k),El00ktomaintain scientific equipment|| |capacity and capability (2021:f41k),f319kforgroup leaders and scientists (2021:f352k)and E783k
(2021;E396k)|| ||Babnce||Transfer|Balance| |---|---|---|---|---| ||1April|Net Incomel|between|31March| |Prior year:|2020
f'000|expenditme
E'000|funds
f'000|2021
f'000| |Unrestricted
funds:||||| |General|5,102|(14,953)|17,355|7,504| |Designated|3,026|(333)|(200)|2,493| |Restricted funds:||||| |Fixed Asset Fund|284,798|||317,191| |Other resn icssd funds:||||| |Fixed Asset Project Support Costs|3,343||(2,750)|| |DP2 phase 2occupation|1,620||(37)|1,224| |154LInterim Insectary|6||(6)|| |BBSRCUKRImre grant funding||18,928|(18,928)|| |Brooksby support costs|||1,573|1,573| |Other|68|||| ||297,963|32,683||330,646| ## ## |Restricted(unde|comprise grants received from funda raspecifically|comprise grants received from funda raspecifically|tobe applied|inthe|acquisition orimprovement|oftangible| |---|---|---|---|---|---|---| |fixed assets orotherwise||applied for such purposes asspecifiedby the grants provided.||||| ||||||2022|2021| ||||||f'000|f'000| |Fixed Asset Fund||||||| |Balance brought|forward||||317,191|284,798| |Grants received|||||24,904|43,687| |Depreciation/impairment||(Note 6)|||(9,684)|(9,469)| |Revenue spend|||||(1.826)|(4,818)| |Transfers|||||(342)|2,993| |Balance carried|forward||||330,243|317,191| ## |Transfers|between funds|||| |---|---|---|---|---| |||Unrestricted|U wstrkbd|| |||general|dedgnased|Restricted| |||funds|funds|funds| |||f'000|f'000|f'000| |Transfer|offunds to general reserves|15,263|250|15,513| ## ## |||||||Investments|||Total| |---|---|---|---|---|---|---|---|---|---| |||||||f'000|||f'000| |Cunent year|||||||||| |Un estrkted funds|||||||||9,790| |Restricted funds|||||||||| |Capital fund|||||||302,945|12,015|314,960| |Fixed Asset|Revaluation||Reswve||||15,283||15,283| |Investment|Property|Revaluation|||Reserve||||| |Other restricted funds|||||||||3,205| ||||||||318,228|25.010|345,238| |||||||||Net current|| |||||||Investments|||Total| |||||||EOOO||f'000|f'000| |Prior year|||||||||| |Unmstrkted|funds||||||||9,997| |Restricted funds|||||||||| |Capital fund|||||||279,873|22,019|301,892| |Revaluation|reserve||||||15,299||15,299| |Other restricted funds||||||||3,458|| ||||||||295,172|35,474|330,fi46| |17FINANCIAL||INSTRUMENTS|||||||| |||||||||2022|2021| |||||||||EOOO|5'000| |Financial assets measured at||||amortised cost||||2,044|9,537| |Financial
liabilities measured||||at amortised cost||||(4,319)|(3,188)| ||||||||||6,349| ## ## |2022|2021| |---|---| |f'000|f'000| |6,113|28,835| |The capital commitments|ofE6,113k(2021:E28|853k)will befunded by the 885RCUKRI capital grants already|awarded.| |---|---|---|---| |(bjOperating lease commitments|||| |The Institute
iscommittedtothefollowingcharges||inrespectof:|| |||2022|2021| |||f'000|f'000| |Land and buMlngs|||| |Within one year||52|52| |IntwotoFive years||218|210| |In over five years|||293| |Plant and Machinery|||| |Within one year|||| |Intwo tofive years|||16| ## ## ## ## ## ##